leflunomide has been researched along with Diabetic Glomerulosclerosis in 4 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Diabetic kidney disease (DKD) combined with Membranous Nephropathy (MN) was observed in some patients with the increasing of Diabetic patients." | 1.72 | Retrospective analysis of leflunomide and low-dose methylprednisolone for the treatment of diabetic nephropathy combined with membranous nephropathy. ( Cui, S; Li, P; Li, Q; Li, W; Shang, S; Wang, C; Wang, W, 2022) |
| "Diabetic nephropathy is one of the most common chronic complications of diabetes with poor efficacy of clinical treatment." | 1.43 | Protective effects of leflunomide on renal lesions in a rat model if diabetic nephropathy. ( He, T; Ji, Y; Lv, W; Wang, J; Zhang, Q, 2016) |
| "Benazepril or LEF treatment significantly prevented body weight loss and 24 h urinary protein excretion induced by diabetes; combined treatment with LEF and benazepril further improved these parameters compared with giving each drug alone (all p < 0." | 1.40 | Synergistic effects of leflunomide and benazepril in streptozotocin-induced diabetic nephropathy. ( Cui, ZH; Jiang, YJ; Jin, H; Jin, HF; Jin, JZ; Jin, YS; Li, C; Li, JJ; Piao, SG; Yang, CW; Zheng, HL, 2014) |
| "Treatment with leflunomide can improve these parameters except systolic blood pressure, BG and HbAlc." | 1.38 | Experimental study of leflunomide on renal protective effect and on inflammatory response of streptozotocin induced diabetic rats. ( Liu, JP; Ren, XJ; Wang, H; Wang, JY; Yu, WM, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shang, S | 1 |
| Cui, S | 1 |
| Wang, W | 1 |
| Wang, C | 1 |
| Li, P | 1 |
| Li, W | 1 |
| Li, Q | 1 |
| Jin, H | 1 |
| Piao, SG | 1 |
| Jin, JZ | 1 |
| Jin, YS | 1 |
| Cui, ZH | 1 |
| Jin, HF | 1 |
| Zheng, HL | 1 |
| Li, JJ | 1 |
| Jiang, YJ | 1 |
| Yang, CW | 1 |
| Li, C | 1 |
| Zhang, Q | 1 |
| Ji, Y | 1 |
| Lv, W | 1 |
| He, T | 1 |
| Wang, J | 1 |
| Yu, WM | 1 |
| Wang, H | 1 |
| Ren, XJ | 1 |
| Liu, JP | 1 |
| Wang, JY | 1 |
4 other studies available for leflunomide and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Retrospective analysis of leflunomide and low-dose methylprednisolone for the treatment of diabetic nephropathy combined with membranous nephropathy.
Topics: Creatinine; Diabetic Nephropathies; Drug Therapy, Combination; Glomerulonephritis, Membranous; Glyca | 2022 |
Synergistic effects of leflunomide and benazepril in streptozotocin-induced diabetic nephropathy.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antifibrinolytic Agents; Benzazepines; Diabetes Me | 2014 |
Protective effects of leflunomide on renal lesions in a rat model if diabetic nephropathy.
Topics: Actins; Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Blood Urea Nitrogen; Body | 2016 |
Experimental study of leflunomide on renal protective effect and on inflammatory response of streptozotocin induced diabetic rats.
Topics: Animals; Anti-Inflammatory Agents; Biomarkers; Chemokine CCL2; Creatinine; Cytoprotection; Diabetes | 2012 |